Shell of NextCure reborn as Avere via reverse merger; $320M-backed IL-23 asset in psoriasis hinges on Phase 2b efficacy data

Bull

A positive readout would be one where AVR-001 achieves statistically significant and clinically meaningful PASI 75/90 response rates versus placebo, with a clean safety profile, demonstrating that the once-weekly dosing convenience observed in Phase 1b translates into Phase 2b efficacy. This would de-risk the IL-23 mechanism in Avere's hands, validate the Hansoh asset acquisition, and provide a clear regulatory pathway to initiate a Phase 3 program, likely driving substantial equity value creation for a company currently valued primarily on pipeline optionality.

Bear

The most likely failure modes are insufficient PASI response rates that fail to differentiate AVR-001 from existing standard of care — particularly if the Phase 1b signal was inflated by patient selection or an uncontrolled design — or an emergent safety signal (e.g., infection risk, hepatotoxicity) that complicates the benefit-risk profile. A disappointing readout would not only terminate the psoriasis program but could call into question whether the $120M upfront and up to $2.18B in milestones paid to Hansoh were justified, leaving the combined company with limited pipeline and a difficult financing environment.